Hanne Callewaert | CEO | AstriVax
Hanne Callewaert (PhD) is co-founder and CEO of AstriVax. She has 20+ years of experience in the life sciences through a PhD in Medical Sciences, Masters in IP, followed by global industry experience in GSK Vaccines as well as into smaller biotech environment, like Oxurion, Oncurious and AstriVax. She has a strong background in regulatory affairs, drug and vaccine development expertise blended with business and corporate development through executive leadership functions as Chief Operating Officer at Oxurion, followed by her current CEO position at AstriVax. She has been involved in development of commercial, late or early stage vaccines, monoclonal antibodies, peptides and small molecules.
AstriVax, a Leuven-based company, founded with a €30 million seed round in 2022, is moving its groundbreaking vaccine platform technology towards clinical Proof of Concept by mid-2024. The Plasmid Launched Live Attenuated Virus vaccine (PLLAV) technology is suitable for prophylactic and therapeutic vaccines, up to immune oncology, with potential of greater efficacy, scalability, reduced cold chain requirements, and speed to market.
The company is working on a prophylactic yellow fever and dual yellow fever-rabies vaccine and on a therapeutic vaccine for chronic hepatis B.Powered by: Hyphen Projects | Connect | Join Global Investor Forum | |||
Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 |
| Register here
|
© Copyright 2023 by Hyphen Projects